Overview

Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
To demonstrate the clinical effectiveness of MK0812 in the treatment of Arthritis.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Oxymetazoline